Skip to content


Developing precision medicines with responder patients in mind

First Investment: 2013

When drugs fail, sometimes it’s not because they don’t work — it’s because they were tested on the wrong population. Auransa’s hypothesis-free machine learning algorithms sort through RNA tran­scrip­tome data to find patients with molecular subtypes of diseases that might respond better to known drug compounds. It offers its technology to partners and is developing its own pipeline of novel drugs for liver cancer and other conditions.

Explore Companies